Ionis Pharmaceuticals (IONS) rocketed in early trading Friday after announcing a $1 billion deal with Biogen (BIIB) to develop treatments for neurological diseases like dementia, following up the success they’ve had with Spinraza.The firms plan to work on neurological diseases including dementia, neuromuscular diseases, movement disorders, ophthalmology, inner-ear diseases and neuropsychiatry.The deal announced Friday extends the collaboration under which the two companies developed Spinraza, a treatment for spinal muscular atrophy.”There is no better partner for Ionis to develop new antisense drugs to treat neurological diseases than Biogen,” Ionis Chief Executive Stanley Crooke said in a prepared statement. “Their demonstrated perseverance, dedication and commitment to innovation in developing drugs for these challenging diseases is unmatched.”
Read the Full Story at www.investors.com
Biogen And Ionis Expand Spinraza Partnership To Neurological Diseases
More from BusinessMore posts in Business »
- Biogen Stays the Wrong Course After a Key Drug Failure
- What Happened? Alzheon Leaves IPO on the Table for the Second Time | Biospace
- Biogen Inks Two Deals to Make Drugs for Neurological Diseases | NASDAQ
- AC Immune inks $1.7bn deal with Lilly, strategic partnership with WuXi | Outsourcing Pharma
- BioXcel Announces Positive Data On Senile Dementia Of Alzheimer’s Type; Stock Up | NASDAQ